Preventing Missing Data Among Concerns In US FDA’s Guidance On COVID-19 Symptom Assessment

 
• By Derrick Gingery

Investigators should plan to find the vital status of discontinued patients, guidances states. Participants need frequent reminders to complete PRO instruments, agency recommends.

Closed up finger on keyboard with word CLINICAL TRIALS
The FDA wants investigators to remind outpatients to fill out COVID-19 PRO instruments to avoid missing data. • Source: Shutterstock

More from Clinical Trials

More from R&D